vasostatin II Inhibitors
Vasostatin II inhibitors are a specialized class of chemical compounds designed to target and inhibit the activity of vasostatin II, a protein fragment derived from the larger precursor protein, vasoactive intestinal peptide (VIP). Vasostatin II is a well-characterized peptide that plays a significant role in regulating various physiological processes, including vascular tone and cell proliferation. This peptide exerts its effects through interactions with specific receptors and intracellular signaling pathways, influencing cellular functions such as migration, adhesion, and growth.
The mechanism of action of vasostatin II inhibitors involves binding to the vasostatin II peptide or its interacting partners, thereby disrupting its ability to modulate cellular processes. By obstructing the interaction of vasostatin II with its receptors or signaling molecules, these inhibitors can interfere with the downstream effects of vasostatin II, such as changes in cell behavior or vascular dynamics. Researchers use vasostatin II inhibitors to investigate the detailed biological roles of this peptide and to explore how its inhibition impacts cellular signaling and physiological processes. This helps in understanding the complex roles of vasostatin II in cellular regulation and vascular function, shedding light on the mechanisms through which this peptide influences cellular and tissue dynamics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Hydroxychloroquine might downregulate vasostatin II by disrupting lysosomal activity and autophagy processes, which are crucial for certain cellular signaling pathways linked to gene expression. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $32.00 $86.00 $150.00 | 3 | |
Sulindac could decrease vasostatin II expression through its inhibition of cyclooxygenase enzymes, thereby reducing angiogenic prostaglandin levels that may control related gene expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid might reduce vasostatin II levels by activating retinoic acid receptors that bind to DNA response elements and repress the transcription of certain angiogenesis-associated genes. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib has the potential to decrease vasostatin II expression by blocking RAF kinase, VEGFR, and PDGFR signaling, leading to a reduced transcriptional activity of angiogenesis-related genes. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib could inhibit vasostatin II production by targeting receptor tyrosine kinases involved in angiogenesis, thereby disrupting downstream transcriptional processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib may decrease vasostatin II levels by inhibiting Bcr-Abl tyrosine kinase and other kinases, leading to a reduction in transcriptional regulators of angiogenesis. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib may lower vasostatin II expression by antagonizing VEGFR, PDGFR, and c-KIT signaling, which could alter the transcriptional network governing angiogenesis. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib could inhibit vasostatin II synthesis by targeting RET and VEGFR, resulting in decreased activity of transcription factors critical for angiogenesis gene expression. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib has the potential to reduce vasostatin II expression by inhibiting EGFR tyrosine kinase, which is involved in the signaling pathways that can dictate the transcriptional regulation of angiogenesis. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib may decrease vasostatin II levels by blocking EGFR, consequently disrupting signaling cascades that control gene expression related to angiogenesis and vascular development. | ||||||